Search results for: Tina Scoones
Filter search results
Recently Published: MCDA to Elicit Stakeholders’ Preferences: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
20 December 2016
…Kent, A. & Hutchings, A. 2013. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health, 16, 1163-9. For more information please contact Martina Garau at OHE….
OHE at HTAi Rome
12 July 2017
…Overall Survival in Oncology from Office of Health Economics Martina Garau presented an empirical exploration of multi-criteria decision analysis: MCDA to Elicit Stakeholders’ Preferences in Italy. The Case of…
Appraising Ultra-Orphan Drugs: Is Cost-per-QALY Appropriate?
22 March 2018
…by a factor of three seem arbitrary. Click here to download the full report. For more information, contact Martina Garau. Zamora, B., Maignen, F., O’Neill, P., Mestre-Ferrandiz, J. and Garau,…
How Should the World Pay for a COVID-19 Vaccine?
31 July 2020
…It builds on work undertaken with Kalipso Chalkidou, Rachel Silverman and Ganesh Ramakrishnan from the Center for Global Development, and Hannah Kettler from PATH, and with Martina Garau and Marina…
Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?
14 April 2021
…2019 review by Baltussen et al., which included OHE’s Martina Garau as an author, noted that “its implementation to date has been criticised for being “entirely mechanistic”, ignoring opportunity costs,…
Early Diagnosis of Visual Defects
1 July 1967
…retina by ophthalmoscopy and selection by family history. The first method detects those who already have a significant loss of function and is thus concerned with established disease rather than…